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JOURNAL OF HEPATOLOGYHepatic encephalopathy treatment and its effect on driving abilities:
A continental divideCHE and QoL, albeit tempered by its relationship with cirrhosis
severity, is being strongly considered in clinical practice. Most
clinicians report that they initiate CHE treatment (with the same
drugs as in OHE) on a case-to-case basis but when asked to
recount cases that were started on CHE treatment in the last
month <5% of those fulﬁlling local CHE criteria were treated.
This could reﬂect the gap between knowledge, attitudes and the
ultimate translation into practice. The respondents felt that there
were still a wide range of unanswered questions regarding CHE
management. Importantly, the 40% who do not engage in CHE
screening are reluctant for several reasons: 43% ﬁnd screening too
time consuming and a similar proportion ﬁnds that lack of consen-
sus and trained personnel hinders screening efforts. These obstacles
seem to be most pronounced in America but have seemingly dimin-
ished since 2007 where a similar query was done [4].
HE and trafﬁc safety
Several studies have shown that HE patients may have difﬁculties
with driving and a convincing 99% agree that covert and recent
overt HE impact on driving skills. Respondents answered driv-
ing-related questions in accordance with their local driving regu-
lations. We found that only 1/5 of the respondents translated this
issue into practice and asked >60% of patients about driving his-
tory, often recommending driving restrictions. On the otherTo the Editor:
We read with great interest the review article on hepatic
encephalopathy (HE) that, in addition to the recent EASL/AASLD
guidelines, is informative about the spectrum of this disease
[1,2]. We set out to evaluate the practice patterns of clinical HE
experts worldwide (285 ISHEN members and authors of clinical
HE articles in the last 5 years) through a systematic electronic
questionnaire focused on the management and effect on driving
ability in HE. Results are summarized in the Table 1.
Response rate was 35%. Respondents were from 23 different
countries in 4 different continents (Europe: n = 48, Americas
n = 28, Asia: n = 21). Sixty per cent specialized in hepatology and
most had more than 10 years of clinical experience.
Management of overt HE (OHE) is similar between continents
and complies with guidelines, although medical management dif-
fers in some aspects: in the US rifaximin is used as much as lactu-
lose (by 96%) but in Europe and Asia branched chain amino acids
(BCAA) and L-ornithine L-aspartate (LOLA) respectively are pre-
ferred after lactulose. This could be due to the unavailability of
LOLA and BCAA in the US. On the other hand <1% from Europe
report probiotic use compared with 20% in the US and Asia, which
could reﬂect real-practice differences. Interestingly, while clinical
impression is used to assess treatment efﬁcacy in most respon-
dents, only 4% of US-based clinicians used blood ammonia levels
in contrast to their European and Asian counterparts.Diagnosis and treatment of covert HE
Sixty percent of clinicians engage in some form of covert HE (CHE)
screening procedure. However, only 1/10 refer the majority of
patients for formal screening. Most clinicians focus screening
efforts on select patient sub-groups: prior overt HE, speciﬁc cog-
nitive complaints from caregiver or patient, and patients’ quality
of life (QoL) issues being the major reasons for screening referral.
As found by others, Portosystemic Encephalopathy Syndrome Test
(PSE) is the preferred psychometric test (41%) along with Critical
Flicker Frequency (CFF) (37%) [3]. As expected there are intercon-
tinental differences: PSE is Europe’s favoured test whereas the
Stroop EncephalApp and CFF are preferred in America and Asia,
respectively. Interestingly, systematic QoL assessment is widely
used (40%) indicating that the established close link between
extreme a similar proportion ask <5% of patients. Most used clin-
ical impression to categorize patients as unsafe drivers, however
some also considered trafﬁc history (45%), psychometric test
results (40%), time since OHE (38%), and caregivers opinion
(37%) in making this judgement. Overall, 79% had at some point
urged patients with recent OHE (<3 months) and 67% with CHE
not to drive; but during the past month driving restrictions had
been recommended in very few patients. In case of any prior, cur-
rently controlled OHE even fewer would recommend driving
restrictions. This inconsistency between knowledge and practice
reﬂects the fact that 75% of respondents ﬁnd it difﬁcult to deal
with trafﬁc safety issues and only half are aware of local laws
which were also interpreted differently.
In this survey of clinical investigators interested in HE, 60% of
respondents offer screening for the presence of CHE via different
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regional strategies: QoL assessment appears to be widely used in
combination with psychometric tests. However, only a few fulﬁll-
ing local CHE criteria are offered treatment and lack of time, per-
sonnel and consensus on key issues appear to be major obstacles.
The majority agree that recent and covert HE impact driving skills
but only a sub-group of HE experts seem to be addressing this in
daily clinical practice. Further clinical studies are needed to
engage the non-HE expert audience and answer the important
remaining questions.
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Table 1. Systematic electronic questionnaire focusing on the management and effect on driving ability in HE patients.
All Europe Americas Asia 
Covert HE management
Offers screening for covert HE 59% 56% 54% 71% 
Preferred screening tools* QoL + PSE QoL + PSE QoL + Stroop test QoL + PSE/CFF
Treatment of CHE was offered:
On case-to-case basis 58% 51% 65% 62%
Never 12% 16% 14% 5%
Always 30% 33% 22% 33%
Drugs used to treat CHE:
Lact/rifax/BCAA/probiotics/LOLA (%)* 94/53/21/15/15 79/42/31/6/10 79/57/0/21/11 85/43/14/19/24
Did not offer screening for CHE 41% 44% 46% 29% 
For those who do not offer screening, the following reasons were stated: 
Lack of time* 43% 22% 78% 35%
Lack of consensus on which tests to use* 38% 27% 54% 35%
Lack of personnel* 41% 34% 69% 0%
Lack of consensus about consequences of screening 44% 39% 54% 35%
I don’t think it is important 0% 0% 0% 0%
HE and traffic safety
Finds it difficult to deal with traffic issues and HE 75% 75% 86% 62%
Obtains traffic history in majority of cases 21% 17% 29% 14%
Are aware of local driving laws in relation to HE 47% 50% 32% 57%
Thinks recent OHE and CHE impacts driving skills 99% 99% 98% 96%
Will restrict driving in
Recent OHE 79% 80% 79% 76%
CHE 67% 67% 46% 76%
Prior, currently controlled HE 48% 42% 57% 52%
Recommended driving restrictions in majority of cases of
Recent OHE (<3 months) 20% 15% 21% 24%
CHE 9% 5% 7% 19%
Prior, currently controlled OHE 7% 6% 0% 14%
Categorizes pts as unsafe driver on the basis of 
specialized tests apart from clinical impression*
40% 54% 21% 29%
Pts, patients; HE, hepatic encephalopathy; CHE, covert hepatic encephalopathy; OHE, overt hepatic encephalopathy; QoL, quality of life; MELD, model for end stage liver
disease; BCAA, branched chain amino acids; LOLA, L-ornithine L-aspartate; PSE, portosystemic encephalopathy syndrome test; CFF, critical ﬂicker frequency.
⁄Different between continents.
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